BackgroundThe identification of high-risk population patients is key to the personalized treatment options for the stage II colorectal cancers. The use of proteomics in the prognosis of patients with
n.a.: Sensitivity and specificity are not available because of a lack of correlation with the primary matched tumors.a: Before/after treatment.Methods used in selected previous reports to detect EGFR
Introduction: The PCM1-JAK2 rearrangement is generated through the t(8; 9)(p22; p24) translocation event. The myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) with PCM1-JAK2 rearrangement is the